ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dulaglutide

Also written as “Dulaglutide”, “LY2189265” and “Dulaglutide (Reference)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 3 companies.

Drug pageDulaglutide: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 21, 201647 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only451 open or runningphase 4since Apr 21, 2016Feb 28, 2008Dec 2027phase 3 · NCT06739122
CSPC Pharmaceutical Groupits history only10 open or runningphase 3since Jan 23, 2024Jan 23, 2024none ahead
Innovent Biologics10 open or runningphase 3since Oct 19, 2022Oct 19, 2022none ahead

Also a collaborator on its studies: United BioSource and Tessella.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2022First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT05606913 · 731 enrolled · China

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently ”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

The one study Innovent Biologics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05606913Diabetes Mellitus, Type 2 · China3CompletedJan 26, 2024731

How it is read

Names in the registry

  • “Dulaglutide”, 25 entries
  • “LY2189265”, 18 entries
  • “dulaglutide”, 2 entries
  • “Dulaglutide (Reference)”, 1 entry
  • “Dulaglutide (Test)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.